Aclarion (NASDAQ:ACON) Rating Increased to Hold at Wall Street Zen

Aclarion (NASDAQ:ACON) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Sunday.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Aclarion in a report on Wednesday, January 21st. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Aclarion currently has an average rating of “Sell”.

Aclarion Stock Performance

Shares of NASDAQ ACON opened at $2.54 on Friday. Aclarion has a 52-week low of $2.34 and a 52-week high of $229.50. The firm has a market capitalization of $2.16 million, a price-to-earnings ratio of -0.17 and a beta of 1.44. The stock has a 50 day moving average price of $4.20 and a 200 day moving average price of $6.23.

About Aclarion

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc and changed its name to Aclarion, Inc in December 2021.